Hepatic Extraction, Metabolism and Biliary Excretion of Doxorubicin in the Isolated Perfused Rat Liver

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1987 Jan 1

PMID 3581417

Citations 13

Authors

F Ballet

P Vrignaud

J Robert

C Rey

R Poupon

Affiliations

Soon will be listed here.

Abstract

The hepatic extraction, metabolism, and biliary excretion of doxorubicin (DX) were studied in the isolated perfused rat liver. Three doses of DX equivalent to 2, 20, and 100 mg/kg in rats were studied over a period of 3 h after bolus injection into the reservoir. DX and metabolites concentration in perfusate, bile, and liver were determined by high-pressure liquid chromatography. The hepatic extraction ratio was low (less than 0.24) and decreased progressively over the 3 h. The hepatic extraction and clearance were significantly lower at the highest dose. Doxorubicinol (DX-OL) was the only metabolite detected in the perfusate, accounting for less than 4% of the total AUC. Thirty-one to thirty-three percent of the dose was excreted into bile over 3 h as unchanged DX. This was reduced to 22% at the highest dose. Only 0.35%-1.33% of the dose was excreted as DX-OL. DX aglycones were found only in the liver, where they represented 20%-30% of the total fluorescence at 3 h. In conclusion, in this model DX has a low extraction ratio, is poorly metabolized and extensively excreted into bile.

Citing Articles

A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars.

Nagpal S, Png Yi Jie J, Malinovskaya J, Kovshova T, Jain P, Naik S ACS Nano. 2024; 18(8):6162-6175.

PMID: 38359902 PMC: 10906076. DOI: 10.1021/acsnano.3c08290.

Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty.

Colloca G, Bellieni A, Di Capua B, Iervolino M, Bracci S, Fusco D Cancers (Basel). 2023; 15(18).

PMID: 37760569 PMC: 10527381. DOI: 10.3390/cancers15184600.

Protective Effects of Omega-3 Supplementation against Doxorubicin-Induced Deleterious Effects on the Liver and Kidneys of Rats.

Espirito Santo S, Monte M, Polegato B, Barbisan L, Romualdo G Molecules. 2023; 28(7).

PMID: 37049766 PMC: 10096317. DOI: 10.3390/molecules28073004.

Doxorubicin metabolism moderately attributes to putative toxicity in prodigiosin/doxorubicin synergism in vitro cells.

Lin S, Lin C, Chen C, Tseng F, Wu T, Weng L Mol Cell Biochem. 2020; 475(1-2):119-126.

PMID: 32754875 PMC: 7599147. DOI: 10.1007/s11010-020-03864-x.

The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats.

Jacevic V, Dragojevic-Simic V, Tatomirovic Z, Dobric S, Bokonjic D, Kovacevic A Int J Mol Sci. 2018; 19(8).

PMID: 30103540 PMC: 6121234. DOI: 10.3390/ijms19082370.

References

Baurain R, Zenebergh A, Trouet A . Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells. J Chromatogr. 1978; 157:331-6. DOI: 10.1016/s0021-9673(00)92350-1. View

Young R, Ozols R, Myers C . The anthracycline antineoplastic drugs. N Engl J Med. 1981; 305(3):139-53. DOI: 10.1056/NEJM198107163050305. View

Ballet F, Barbare J, Poupon R . Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1984; 20(6):761-4. DOI: 10.1016/0277-5379(84)90213-x. View

Peters J, Gordon G, Kashiwase D, ACTON E, Hunt C . Metabolic disposition of N,N-dibenzyldaunorubicin in the rat. Cancer Res. 1983; 43(4):1477-87. View

SKIBBA J, Jones F, Condon R . Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. Cancer Treat Rep. 1982; 66(6):1357-63. View

Boston R, Phillips D . Evidence of possible dose-dependent doxorubicin plasma kinetics in man. Cancer Treat Rep. 1983; 67(1):63-9. View

Benjamin R, Riggs Jr C, Bachur N . Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther. 1973; 14(4):592-600. DOI: 10.1002/cpt1973144part1592. View

Winkler K, Bass L, Keiding S, Tygstrup N . The physiologic basis for clearance measurements in hepatology. Scand J Gastroenterol. 1979; 14(4):439-48. View

Powis G, Ames M, Kovach J . Dose-dependent pharmacokinetics and cancer chemotherapy. Cancer Chemother Pharmacol. 1981; 6(1):1-9. DOI: 10.1007/BF00253003. View

10.

Hartman N, Basseches P, Powis G . Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat. Cancer Chemother Pharmacol. 1982; 10(1):11-5. DOI: 10.1007/BF00257229. View

11.

Klaassen C, Watkins 3rd J . Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev. 1984; 36(1):1-67. View

12.

Wilkinson G, SHAND D . Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975; 18(4):377-90. DOI: 10.1002/cpt1975184377. View

13.

Garnick M, ENSMINGER W, Israel M . A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res. 1979; 39(10):4105-10. View

14.

ARCAMONE F, Lazzati M, Vicario G, Zini G . Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study. Cancer Chemother Pharmacol. 1984; 12(3):157-66. DOI: 10.1007/BF00256538. View

15.

Miller L, BLY C, Watson M, BALE W . The dominant role of the liver in plasma protein synthesis; a direct study of the isolated perfused rat liver with the aid of lysine-epsilon-C14. J Exp Med. 1951; 94(5):431-53. PMC: 2180336. DOI: 10.1084/jem.94.5.431. View

16.

Riggs Jr C, Benjamin R, SERPICK A, Bachur N . Bilary disposition of adriamycin. Clin Pharmacol Ther. 1977; 22(2):234-41. DOI: 10.1002/cpt1977222234. View

17.

Wilkinson P, Israel M, Pegg W, Frei 3rd E . Comparative metabolism and excretion of adriamycin in man, monkey, and rat. Cancer Chemother Pharmacol. 1979; 2(2):121-5. DOI: 10.1007/BF00254084. View

18.

Bass L, Keiding S, Winkler K, Tygstrup N . Enzymatic elimination of substrates flowing through the intact liver. J Theor Biol. 1976; 61(2):393-409. DOI: 10.1016/0022-5193(76)90026-6. View

19.

Israel M, Wilkinson P, Pegg W, Frei 3rd E . Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat. Cancer Res. 1978; 38(2):365-70. View

20.

Celio L, DiGregorio G, RUCH E, Pace J, Piraino A . Doxorubicin concentrations in rat plasma, parotid saliva, and bile and protein binding in rat plasma. Arch Int Pharmacodyn Ther. 1982; 260(2):180-8. View